Category: Parkinson’s

New real-world data for ONGENTYS®▼ (opicapone) released at the MDS

Posted on 22 September, 2020 - Parkinson’s Disease

New data presented 12-16 September at the MDS 2020 Virtual Congress further support the efficacy and tolerability of ONGENTYS® (opicapone) observed in pivotal Phase III studies. Opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved for the treatment of end-of-dose motor fluctuations in adult PD patients taking levodopa. A new post-hoc analysis of the real-world OPTIPARK study showed that the majority of treatment-emergent…